Intensive showed no clear difference in mortality at day 30 compared with less intensive continuous renal replacement therapy (CRRT) (low certainty).
Intensive showed no clear difference in mortality after 30 days post‐randomisation compared with less intensive continuous renal replacement therapy (CRRT) (low certainty).
Intensive showed no clear difference in patients free of RRT after discontinuing CRRT compared with less intensive continuous renal replacement therapy (CRRT) (low certainty).
Intensive leads to higher adverse events: hypophosphataemia compared with less intensive continuous renal replacement therapy (CRRT) (high certainty).
Intensive showed no clear difference in mortality: patients with sepsis compared with less intensive continuous renal replacement therapy (CRRT) (low certainty).
Intensive showed no clear difference in mortality: patients without sepsis compared with less intensive continuous renal replacement therapy (CRRT) (low certainty).
Intensive leads to lower mortality: patients with AKI related to cardiac or general surgery compared with less intensive continuous renal replacement therapy (CRRT) (high certainty).
Intensive showed no clear difference in mortality: patients with AKI not related to surgery compared with less intensive continuous renal replacement therapy (CRRT) (low certainty).
Angiotensin receptor blockers showed no clear difference in all‐cause death Median compared with angiotensin‐converting‐enzyme inhibitors (low certainty).
Angiotensin receptor blockers showed no clear difference in cardiovascular death Median compared with angiotensin‐converting‐enzyme inhibitors (low certainty).
Angiotensin receptor blockers showed no clear difference in doubling of SCr Median compared with angiotensin‐converting‐enzyme inhibitors (low certainty).
Angiotensin receptor blockers showed no clear difference in fatal or nonfatal stroke Median compared with angiotensin‐converting‐enzyme inhibitors (low certainty).
Angiotensin receptor blockers showed no clear difference in fatal or nonfatal myocardial infarction Median compared with angiotensin‐converting‐enzyme inhibitors (low certainty).
Angiotensin receptor blockers showed no clear difference in micro‐ to macroalbuminuria Median compared with angiotensin‐converting‐enzyme inhibitors (low certainty).
Angiotensin receptor blockers showed no clear difference in micro‐ to normoalbuminuria Median compared with angiotensin‐converting‐enzyme inhibitors (low certainty).
Angiotensin receptor blockers (ARBs) showed no clear difference in anuria compared with angiotensin‐converting enzyme inhibitors (ACEis) (moderate certainty).
Angiotensin receptor blockers (ARBs) showed no clear difference in cardiovascular events (non‐fatal) compared with angiotensin‐converting enzyme inhibitors (ACEis) (moderate certainty).